{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:03:46Z","timestamp":1771315426607,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    There are no clinically meaningful differences between bio\u2010originators (BO) and their biosimilars (BS) in safety and efficacy. However, differences in pharmaceutical properties, such as volume and excipient, can occur. This study aimed to compare outcomes between patients transitioning from the modernized adalimumab BO (0.4\u2009mL\/no citrate) to BS1 (0.8\u2009mL\/citrate) and from BS1 to BS2 (0.4\u2009mL\/no citrate) and outcomes for new starters. In this retrospective exploratory cohort study of RA, PsA, and axial SpA patients receiving adalimumab, the (adjusted) 12\u2010month drug survival rates were compared between the transition from the modernized BO to BS1 (Cohort 1, 2021) and from BS1 to BS2 (Cohort 2, 2023) in existing users, and for adalimumab\u2010na\u00efve new starters of the originator and BS1 and BS2 (Cohorts 3 to 5). Subanalyses included drug survival separately for inefficacy and intolerability. In existing users, 983 patients transitioned to BS1, 1082 patients to BS2, with 659 patients in both cohorts. Drug survival rates at 12\u2009months were 73% (95% CI: 70\u201376) and 90% (95% CI: 88\u201392), respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), adjusted hazard rate ratio (HRR) 0.32 (95% CI: 0.26\u20130.40) in favor of BS2. The HRR for discontinuation due to inefficacy and tolerability were 0.50 (95% CI: 0.37\u20130.67) and 0.20 (95% CI: 0.14\u20130.28), respectively, both favoring BS2. In adalimumab\u2010na\u00efve new starters also, better survival for the originator and BS2 were seen compared with BS1. In conclusion, adalimumab BS1 showed a significantly lower drug survival than BS2, primarily due to lower tolerability. These findings suggest that pharmaceutical differences can have an important impact on drug survival.\n                  <\/jats:p>","DOI":"10.1002\/cpt.70098","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:33:44Z","timestamp":1761219224000},"page":"651-659","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter"],"prefix":"10.1002","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6802-1898","authenticated-orcid":false,"given":"Amy C.D.","family":"Peeters","sequence":"first","affiliation":[{"name":"Department of Rheumatology Sint Maartenskliniek  Ubbergen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-9378","authenticated-orcid":false,"given":"Maike H.M.","family":"Wientjes","sequence":"additional","affiliation":[{"name":"Department of Research Sint Maartenskliniek  Ubbergen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5893-9171","authenticated-orcid":false,"given":"Wieland D.","family":"M\u00fcskens","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Sint Maartenskliniek  Ubbergen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7236-0358","authenticated-orcid":false,"given":"David F.","family":"Ten Cate","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Sint Maartenskliniek  Ubbergen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8560-9514","authenticated-orcid":false,"given":"Bart J. F.","family":"van den Bemt","sequence":"additional","affiliation":[{"name":"Department of Research Sint Maartenskliniek  Ubbergen The Netherlands"},{"name":"Department of Pharmacy Sint Maartenskliniek  Ubbergen The Netherlands"},{"name":"Department of Pharmacy Pharmacology and Toxicology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9527-851X","authenticated-orcid":false,"given":"Noortje","family":"van Herwaarden","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Sint Maartenskliniek  Ubbergen The Netherlands"},{"name":"Department of Pharmacy Pharmacology and Toxicology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-4079","authenticated-orcid":false,"given":"Alfons A.","family":"den Broeder","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Sint Maartenskliniek  Ubbergen The Netherlands"},{"name":"Department of Research Sint Maartenskliniek  Ubbergen The Netherlands"},{"name":"Department of Rheumatology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"e_1_2_11_1_1","first-page":"86","article-title":"Key concepts in biosimilar medicines: what physicians must know","volume":"9","author":"Iskit A.B.","year":"2022","journal-title":"North Clin. Istanb."},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00526-w"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00259-8"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638444"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15101"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000987"},{"key":"e_1_2_11_7_1","first-page":"532","article-title":"Multiple switching between the biosimilar adalimumab PF\u201006410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open\u2010label, randomised, parallel\u2010group study. The lancet","volume":"5","author":"Prof Roy M.","year":"2023","journal-title":"Rheumatology"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3640"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00473-2"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00546-6"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00213-8"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm\u20102024\u2010004379"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02818-9"},{"key":"e_1_2_11_14_1","unstructured":"Idacio (adalimumab). European Medicines Agency (2019)."},{"key":"e_1_2_11_15_1","unstructured":"Yuflyma (adalimumab). European Medicines Agency (2021)."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0117"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204920"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-3514.35.4.250"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.2846"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3198"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2218504"},{"issue":"1","key":"e_1_2_11_22_1","first-page":"1794","article-title":"AB1127\u2009the retention rate of etanercept and adalimumab in first\u2010line and after non\u2010medical switch in patients with psoriatic arthritis: A comparison between originators and biosimilars. A single\u2010center retrospective study","volume":"82","author":"Rella V.","year":"2023","journal-title":"Ann. Rheumat. Dis."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04679-y"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S256715"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40324"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2017.10.003"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40516"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17437199.2021.1970610"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70098","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70098","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:10:46Z","timestamp":1771312246000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cpt.70098"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70098","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"2025-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}